Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 in Advanced Solid Tumors
NCT04623892Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2618 in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
TQB2618
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04623892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623892.